Promising breast cancer combo trial pulled before it even started

NCT ID NCT07134556

Terminated Disease control Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This was a phase II trial testing a combination of three drugs—zimberelimab, domvanalimab, and sacituzumab govitecan—as a first treatment for people with advanced triple-negative breast cancer that is PD-L1 positive. The study aimed to see how well the drugs shrank tumors and how safe they were. However, the trial was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zimberelimab, domvanalimab, and sacituzumab govitecan
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with advanced triple-negative breast cancer that is PD-L1 positive.
What could go wrong: This trial was withdrawn before enrolling any participants, so no data on safety or effectiveness exist. The combination may cause significant side effects and may not work better than existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PDL-1 POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PDL-1 POSITIVE TRIPLE NEGATIVE BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.